| 1 |
programmed death-ligand 1
(4104 times)
|
Neoplasms
(1809 times)
|
PD-1 (1008 times)
NSCLC (641 times)
OS (476 times)
|
2004 Schistosoma mansoni worms induce anergy of T cells via selective up-regulation of programmed death ligand 1 on macrophages.
|
| 2 |
PD-1 ligand
(278 times)
|
Neoplasms
(105 times)
|
PD-1 (192 times)
CTLA-4 (32 times)
NSCLC (31 times)
|
2001 Laser capture microdissection-based expression profiling identifies PD1-ligand as a target of the nude locus gene product.
|
| 3 |
protein ligand 1
(48 times)
|
Neoplasms
(18 times)
|
NSCLC (13 times)
ICIs (11 times)
CTLA-4 (7 times)
|
2016 Near infrared photoimmunotherapy with avelumab, an anti-programmed death-ligand 1 (PD-L1) antibody.
|
| 4 |
PD-1 and its ligand
(9 times)
|
Neoplasms
(3 times)
|
PD-1 (2 times)
Abs (1 time)
EBV (1 time)
|
2007 Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection.
|
| 5 |
anti-PD-ligand 1
(7 times)
|
Neoplasms
(3 times)
|
PD-1 (5 times)
CTLA-4 (3 times)
ACC (1 time)
|
2017 Biomarkers to predict prognosis and response to checkpoint inhibitors.
|
| 6 |
programmed death-1 receptor and its ligand
(4 times)
|
Neoplasms
(2 times)
|
CT (1 time)
CTLA-4 (1 time)
irAEs (1 time)
|
2014 Treatment paradigms for patients with metastatic non-small cell lung cancer, squamous lung cancer: first, second, and third-line.
|
| 7 |
programmed cell death 1
(3 times)
|
Medicine
(1 time)
|
HNSCC (2 times)
CTLA-4 (1 time)
eTregs (1 time)
|
2018 Mouse-Derived Gastric Organoid and Immune Cell Co-culture for the Study of the Tumor Microenvironment.
|
| 8 |
anti-PD-1 ligand
(2 times)
|
Neoplasms
(1 time)
|
PD-1 (2 times)
CLL (1 time)
DCs (1 time)
|
2020 Triggering interferon signaling in T cells with avadomide sensitizes CLL to anti-PD-L1/PD-1 immunotherapy.
|
| 9 |
programmed death protein-ligand 1
(2 times)
|
Neoplasms
(2 times)
|
PD-1 (1 time)
smRCC (1 time)
VEGFR2 (1 time)
|
2020 New emerging targets in cancer immunotherapy: the role of VISTA.
|
| 10 |
programmed death-ligand 1 receptor
(2 times)
|
Neoplasms
(2 times)
|
OS (2 times)
AR (1 time)
BMI (1 time)
|
2019 Prognostic markers in salivary gland cancer and their impact on survival.
|
| 11 |
1-PD-1-ligand
(1 time)
|
Biological Therapy
(1 time)
|
APCs (1 time)
CTLA-4 (1 time)
PD (1 time)
|
2003 T cell costimulatory pathways: blockade for autoimmunity.
|
| 12 |
anti-anti-Programmed Death Ligand-1
(1 time)
|
Neoplasms
(1 time)
|
ICI (1 time)
mccRCC (1 time)
NSCLC (1 time)
|
2021 Tumor Microenvironment Features as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors (ICI) in Metastatic Clear Cell Renal Cell Carcinoma (mccRCC).
|
| 13 |
demonstratedprogrammed death ligand-1
(1 time)
|
|
GI (1 time)
IHC (1 time)
NCCN (1 time)
|
2020 Gastric Cardia Adenocarcinoma with Metastasis to the Scalp: A Case Report.
|
| 14 |
PD-1 and its 2 B7 family ligands, B7-H1
(1 time)
|
Hematology
(1 time)
|
CTLs (1 time)
HA (1 time)
|
2007 Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells.
|
| 15 |
PD-1 engagement to its ligand
(1 time)
|
Molecular Biology
(1 time)
|
CMV (1 time)
PD-1 (1 time)
|
2006 Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction.
|
| 16 |
PD-1 ligand expression
(1 time)
|
Neoplasms
(1 time)
|
CTLA-4 (1 time)
PD-1 (1 time)
SITC (1 time)
|
2016 Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation.
|
| 17 |
PD-1 ligand-positive T cells
(1 time)
|
Allergy and Immunology
(1 time)
|
IFN (1 time)
IL (1 time)
MTB (1 time)
|
2016 Programmed death-1+ T cells inhibit effector T cells at the pathological site of miliary tuberculosis.
|
| 18 |
PD-1 on CD4+CD25+ Tregs, CD19+ cells and its ligand
(1 time)
|
Allergy and Immunology
(1 time)
|
BI (1 time)
|
2016 Increased IL-35 producing Tregs and CD19+IL-35+ cells are associated with disease progression in leprosy patients.
|
| 19 |
PD-1 on Tcells and its ligand
(1 time)
|
Biological Science Disciplines
(1 time)
|
APCs (1 time)
|
2018 Antigen-Presenting Cell-Intrinsic PD-1 Neutralizes PD-L1 in cis to Attenuate PD-1 Signaling in T Cells.
|
| 20 |
PD-1 on Tregs, B cell and its ligand
(1 time)
|
Allergy and Immunology
(1 time)
|
BI (1 time)
|
2016 Increased IL-35 producing Tregs and CD19+IL-35+ cells are associated with disease progression in leprosy patients.
|
| 21 |
PD-1 receptor ligand
(1 time)
|
Immune System Diseases
(1 time)
|
PD-1 (1 time)
|
2014 Autoimmunity as a double agent in tumor killing and cancer promotion.
|
| 22 |
PD-1, namely, B7-H1
(1 time)
|
Allergy and Immunology
(1 time)
|
DCs (1 time)
PD-1 (1 time)
|
2002 Expression of programmed death 1 ligands by murine T cells and APC.
|
| 23 |
PD-1, the ligand of which
(1 time)
|
Antineoplastic Agents
(1 time)
|
PD-1 (1 time)
|
2018 Improved outcomes with pembrolizumab treatment in two cases of double cancer including non-small-cell lung cancer.
|
| 24 |
PD-1-PD-ligand 1
(1 time)
|
Allergy and Immunology
(1 time)
|
IFN (1 time)
IL (1 time)
MTB (1 time)
|
2016 Programmed death-1+ T cells inhibit effector T cells at the pathological site of miliary tuberculosis.
|
| 25 |
PD-L1 and TGF-beta than patients with advanced invasive thymic carcinoma
(1 time)
|
|
OS (1 time)
PFS (1 time)
TETs (1 time)
|
2018 Impact of PD-L1, transforming growth factor-beta expression and tumor-infiltrating CD8+ T cells on clinical outcome of patients with advanced thymic epithelial tumors.
|
| 26 |
PD-L1 and, more recently, chromosomal 9p24.1/CD274
(1 time)
|
Pathology
(1 time)
|
FISH (1 time)
IHC (1 time)
PD-L2 (1 time)
|
2018 Immune checkpoint blockade as a potential therapeutic strategy for undifferentiated malignancies.
|
| 27 |
PD-L1 IHC
(1 time)
|
Pathology
(1 time)
|
NSCLC (1 time)
|
2016 [Predictive PD-L1 immunohistochemistry for non-small cell lung cancer : Current state of the art and experiences of the first German harmonization study].
|
| 28 |
PD-L1 protein expression using two IHC assays, mRNA
(1 time)
|
Neoplasms
(1 time)
|
NSCLC (1 time)
|
2019 PD-L1 gene copy number and promoter polymorphisms regulate PD-L1 expression in tumor cells of non-small cell lung cancer patients.
|
| 29 |
PD-L1 TM
(1 time)
|
Neoplasms
(1 time)
|
OS (1 time)
PD-L1 ME (1 time)
PFS (1 time)
|
2020 Prognostic significance of EGFR, MUC1 and PD-L1 expressions in cases with triple negative breast cancer.
|
| 30 |
PD-L1High
(1 time)
|
Neoplasms
(1 time)
|
ALDH (1 time)
PD-1 (1 time)
TNBCs (1 time)
|
2019 WNT signaling modulates PD-L1 expression in the stem cell compartment of triple-negative breast cancer.
|
| 31 |
plasma cells, are CD19-negative, and express B7-H1
(1 time)
|
Hematology
(1 time)
|
MM (1 time)
|
2009 A subpopulation of malignant CD34+CD138+B7-H1+ plasma cells is present in multiple myeloma patients.
|
| 32 |
production of T cells via interaction with its ligands, B7-H1
(1 time)
|
Allergy and Immunology
(1 time)
|
---
|
2013 Negative role of inducible PD-1 on survival of activated dendritic cells.
|
| 33 |
programmed cell death ligand 1 antibody
(1 time)
|
Physicochemical Phenomena
(1 time)
|
Treg (1 time)
|
2019 Regulatory T Cells Tailored with pH-Responsive Liposomes Shape an Immuno-Antitumor Milieu against Tumors.
|
| 34 |
programmed cell death receptor-1
(1 time)
|
Allergy and Immunology
(1 time)
|
DCs (1 time)
LPS (1 time)
MSCs (1 time)
|
2016 Mesenchymal Stem Cells Upregulate the Expression of PD-L1 But Not VDR in Dendritic Cells.
|
| 35 |
Programmed Death Cell Ligand 1
(1 time)
|
Pulmonary Medicine
(1 time)
|
OS (1 time)
TIMs (1 time)
|
2017 Programmed Death Cell Ligand 1 (PD-L1) Is Associated With Survival in Stage I Non-Small Cell Lung Cancer.
|
| 36 |
programmed death-1 molecule ligand 1
(1 time)
|
Allergy and Immunology
(1 time)
|
CVID (1 time)
HLA-DR (1 time)
Ig (1 time)
|
2012 Monocyte activation is a feature of common variable immunodeficiency irrespective of plasma lipopolysaccharide levels.
|
A Search Service for Abbreviation / Long Form